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scriptase inhibitors (RTI) and protease inhibitors (PI).
However, lifelong therapy and a high mutation rate of the
virus lead to the emergence of strains resistant to cur-
rently used drugs. Resistance to the applied antiretroviral
therapy results in increasing plasma viral load and con-
comitant decrease of the CD4 cell count.
An increase of resistance in newly infected persons
from 4% in 1996 – 1998 to 17% in 1999 – 2001 has been
observed (Ristig et al., 2002), and complex mutation pat-
terns have been identified in individual patients. Because
of their growing importance, various resistance assays
have been developed and incorporated into patient
management. The common rationale of these assays is
to detect resistance when rising viral loads indicate failing
antiretroviral therapy.
There are two different approaches for the determina-
tion of HIV resistance: genotypic and phenotypic assays.
Genotypic resistance tests are based on the detection of
mutations in the RT and/or PR gene, mostly done by nu-
cleotide sequencing, and assessment of their associa-
tion with drug resistance using commercial software or
databases from the Internet, or expert advice. Phenotyp-
ic assays measure empirically the sensitivity of the RT
and/or PR toward the therapeutically used inhibitors
(Harrigan and Cote, 2000; Schmidt et al., 2002). Thus
phenotypic resistance factors are derived directly from
experimental values, whereas in genotypic analysis the
degree of resistance is deduced by interpretation of dif-
ferent mutations and their interactions based on pheno-
typic and clinical experience. Most phenotypic resist-
ance assays measure the effect of PI and/or RTI on HIV
replication in cell culture (Garcia-Lerma and Heneine,
2001). RT and PR genes are amplified from patient mate-
rial and inserted into an HIV vector deficient for the re-
spective genes; these constructs are then transfected
into cultured cells permissive for HIV replication. Replica-
tion of the recombinant virus is determined in the pres-
ence and absence of RTI or PI using reporter genes for
quantification. Two test systems are commercially avail-
able, Antivirogram (Virco, Mechelen, Belgium; Hertogs
et al., 1998) and PhenoSense (ViroLogic, South San Fran-
cisco, USA; Petropoulos et al., 2000). These assays are
complex, very laborious and expensive. They require
several weeks for completion (Flexner, 2000). Further-
more, they cannot detect the so-called ‘quasispecies’
(Domingo et al., 1985, 1995) present in low proportions
(Rodriguez-Rosado et al., 1999; Petropoulos et al., 2000).
Distinct subpopulations may be selected for in replica-
tion-based assays, leading to erroneous resistance fac-
tors that are not representative for the patient’s virus pop-
ulation.
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A phenotypic resistance test based on recombinant
expression of the active HIV protease in E. coli from
patient blood samples was developed. The protease
is purified in a rapid one-step procedure as active
enzyme and tested for inhibition by five selected
synthetic inhibitors (amprenavir, indinavir, nelfinavir,
ritonavir, and saquinavir) used presently for chemo-
therapy of HIV-infected patients. The HPLC system
used in a previous approach was replaced by a contin-
uous fluorogenic assay suitable for high-throughput
screening on microtiter plates. This reduces signifi-
cantly the total assay time and allows the determina-
tion of inhibition constants (Ki). The Michaelis
constant (Km) and the inhibition constant (Ki) of
recombinant wild-type protease agree well with pub-
lished data for cloned HIV protease. The enzymatic
test was evaluated with recombinant HIV protease de-
rived from eight HIV-positive patients scored from
‘sensitive’ to ‘highly resistant’ according to mutations
detected by genotypic analysis. The measured Ki val-
ues correlate well with the genotypic resistance
scores, but allow a higher degree of differentiation.
The non-infectious assay enables a more rapid yet
sensitive detection of HIV protease resistance than
other phenotypic assays.
Key words: Fluorogenic assay /High-throughput
screening /HIV protease /HIV protease inhibitor /
Quenched substrate /Resistance.
Introduction
Introduction of HAART (Highly Active Antiretroviral Ther-
apy) has significantly improved both life expectance and
quality of HIV-positive patients (Richman, 2001). The viral
reverse transcriptase (RT) and protease (PR) are the tar-
get enzymes for a combined therapy with reverse tran-
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In view of the increasing spread of inhibitor-resistant
HIV strains, indications for resistance testing have been
expanded (EuroGuidelines Group for HIV Resistance,
2001), including primary testing even before the initiation
of HAART. In these clinical situations, a sensitive detec-
tion of viral subpopulations within a short diagnostic time
seems highly desirable. To approach these requirements,
we have introduced an enzymatic assay for the inhibition
of patient-derived recombinant HIV protease by thera-
peutical PI using HPLC methodology (Gehringer et al.,
2003). Here we describe an improved assay comprising
recombinant expression of PR from patient-derived
RNA/cDNA in E. coli cells and measurement of the enzy-
matic activity with a fluorogenic substrate in a microtiter
plate-based high-throughput system. This test is the first
that allows a precise determination of individual inhibition
constants (Ki) of therapeutic PI for patient-derived PR
and thus seems suitable as a fast PR-based phenotypic
resistance test in clinical virology.
Results
Expression and Purification of Patient-Derived HIV
Protease
Starting with viral RNA from patient plasma, reverse-tran-
scribed into cDNA, HIV PR for the resistance assays was
obtained by expression of the PCR-amplified PR gene in
E. coli as described in Materials and Methods. Taking ad-
vantage of the high acid stability of PR, the enzyme was
purified in a one-step acid procedure (von der Helm et al.,
1994). As reference for the establishment of the test sys-
tem, recombinant HIV-1 wild-type PR (clade B MVP899-
87 isolate; Gürtler et al., 1994) was expressed and puri-
fied as above and then further purified in a second step
resulting in >70% purity (von der Helm et al., 1994;
Gehringer et al., 2003). Preparation of recombinant PR
from patient plasma takes 5 days and can be paused and
continued later at several preparation levels of the proto-
col.
PR Activity Assay
Enzymatic activity of HIV PR was measured with the
quenched fluorogenic peptide substrate DABCYL-γ-
Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS that con-
tains the gag/p17/p24 cleavage site of the gag precursor
substrate between Tyr and Pro (Matayoshi et al., 1990).
This octapeptide comprising the cleavage site is C-termi-
nally linked to the fluorophore EDANS that is quenched
by the N-terminal DABCYL residue via intramolecular flu-
orescence resonance energy transfer (FRET). Cleavage
by HIV PR leads to increased fluorescence. At 480 nm
emission wavelength equimolar solutions of the cleavage
products and of pure EDANS generated the same fluo-
rescence signal (data not shown), allowing calibration
with EDANS (see below).
The fluorogenic assay was established in cuvettes and
later transferred to 96-well microtiter plates (see Materi-
als and Methods for detailed test protocols). A relatively
high DMSO concentration (10%) improved the solubility
of both the hydrophobic substrate and PR without signif-
icantly affecting protease activity. Addition of the deter-
gent NP-40 in a concentration above the critical micellar
concentration stabilized the protease, ensuring a con-
stant proteolytic activity during the duration of the test
(data not shown). Thus even low residual PR activities in
the range of 0.2 – 1 nM×min– 1 could be reproducibly de-
termined. From several types of black 96-well plates,
those with a clear bottom allowed the most sensitive de-
tection of fluorescence through the bottom of the wells.
Calculation of reaction rates (nM×min– 1) from the
progress curves was based on calibration with EDANS in
the presence of substrate (10 µM). Figure 1 shows a typi-
cal calibration curve fitted to 5 data points measured on
microtiter plates with different EDANS concentrations
that were selected according to the expected substrate
turnover during the whole duration of an assay. The linear
correlation between fluorescence signal and EDANS
concentration indicates the absence of significant inter-
molecular quenching within the investigated concentra-
tion range. The slope of the calibration line (51.8 RFU×
nM– 1 in Figure 1) was used to convert the sampled fluo-
rescence signals (RFU) into the concentrations of the flu-
orescent cleavage product (nM). The reaction rate, ex-
pressed as increase of product concentration per min
(nM×min– 1), was stable over the measurement time under
conditions of negligible substrate depletion.
Determination of Inhibition Constants
The inhibition of PR by five therapeutically employed PI
(amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir)
was determined in our test system. Dependence of the
residual activities (vi/vo in the presence of inhibitor) on PI
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Fig. 1 EDANS Calibration of Microtiter Plate Fluorescence
Readings.
RFU, relative fluorescence units. The calibration line (slope: 51.8
RFU×nM– 1) was obtained by linear regression analysis of the
data measured in duplicate in different wells (R=0.99988).
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concentration was not linear, indicating equilibrium
between enzyme and inhibitor (Figure 2). Each PI con-
centration was tested in duplicate, revealing high well-to-
well reproducibility. In order to define the type of inhibi-
tion (Bieth, 1995), classical ([Et]/Ki<0.1) or tight-binding
(0.1<([Et]/Ki)<10), we determined the total enzyme con-
centration, [Et], by approaching titration conditions ([Et]/Ki
~10). For this purpose, the initial rate without inhibitor
was adjusted to a range of 100 to 200 nM×min– 1 and the
rate was followed for only a few minutes in order to mini-
mize substrate depletion. Data [(vi/vo) and the correspon-
ding PI concentrations] from these quasi-titration experi-
ments (Knight, 1995) with amprenavir fitted with equation
(1) (see Materials and Methods) allowed the estimation of
apparent [Et] and the calculation of apparent kcat=vo/[Et] at
10 µM substrate concentration (Table 1). Identical results
were obtained for two samples of the same patient (6a
and 6b) that were amplified and expressed indepen-
dently. From kcat the active PR concentrations in the
corresponding equilibrium inhibition experiments were
calculated and were found to be in the same range
(0.1 – 0.2 nM) as the inhibition constants for wild-type PR
and inhibitor-sensitive PR from patients, indicating the
prevalence of tight-binding conditions. Fitting of equilib-
rium inhibition data with equation (1) after entering [Et]
(calculated from the corresponding amprenavir quasi-
titration experiment) as a fixed parameter yielded reliable
results for the Ki values and the calculated resistance fac-
tors (see below and Tables 2 – 5). Therefore this proce-
dure was generally applied for testing wild-type and pa-
tient-derived PR, except when patient-derived PR was
highly resistant to amprenavir. In these cases of very high
Ki for amprenavir, quasi-titration with amprenavir was not
feasible ([Et]/Ki ~ 10 could not be reached), but as then
the condition [Et]/Ki<0.1 was fulfilled, the data were fitted
to equation (2) for ‘classical’ inhibition where [Et] is negli-
gible (see Materials and Methods for details).
Substrate Affinity and Inhibition of Wild-Type PR
As a reference for the analysis of patient-derived PR, we
determined the enzymatic parameters (Km, kcat) of recom-
binant wild-type (WT) PR and its inhibition constants (Ki)
for the five therapeutic PI. The Michaelis-Menten con-
stant of WT PR was determined by measuring the sub-
strate turnover at different substrate concentrations and
fitting the data to the Michaelis-Menten equation (data
not shown). The poor solubility of substrate prevented the
use of concentrations higher than 60 µM. For WT PR we
obtained a Km of 80 µM, comparing well with 103 µM re-
ported previously (Matayoshi et al., 1990). This value con-
firms that the substrate concentration of 10 µM used in our
assays is well below Km and correction of Ki for substrate
competition according equation (3) is not relevant.
WT PR either highly purified (>70%) or one-step puri-
fied (von der Helm et al., 1994) was tested for inhibition by
PIs in cuvettes and on microtiter plates. To achieve high
accuracy, the Ki for WT PR was determined from 15 to 20
data points. Table 2 shows that inhibition constants are
not significantly dependent on the degree of enrichment
of HIV PR or on the format (cuvette or microtiter plate) of
the enzymatic test. According to these data, the pres-
ence of contaminating E. coli proteins (data not shown)
does not influence the inhibition constants. Our results
agree well with data from the literature where the extent
of cleaved substrate was determined by ion-exchange
HPLC (Klabe et al., 1998) or with the same fluorogenic
peptide substrate as in this work (Markgren et al., 2001).
The crude preparation of patient-derived PR used in our
work was therefore sufficient to obtain accurate and valid
results, a feature that facilitates and accelerates the test
procedure considerably.
PI Resistance of Patient-Derived HIV Proteases
To evaluate the potential of our test system for resistance
screening, we investigated the inhibition of recombinant-
ly expressed HIV PR from 8 patients that had been geno-
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Fig. 2 Inhibition of a Patient-Derived PR by Amprenavir.
vo, initial reaction rate in the absence of inhibitor; vi, reaction
rates in the presence of increasing concentrations of ampre-
navir. The inhibition curve (line) was obtained by fitting the data
(measured in duplicate in different wells) to equation (1).
Table 1 Amprenavir Titration of Wild-Type and Patient-Derived
HIV Protease.
HIV PR Initial rate, vo PR concentration, Et kcat [S]=10 µM
(nM×min– 1) (nM) (s– 1)
WT 189 8.1 0.39
Mutant a 205 26.8 0.13
PR 4 195 3.7 0.88
PR 7 191 3.5 0.91
PR 8 197 3.4 0.97
PR 6a 174 4.5 0.64
PR 6b 203 5.2 0.65
The total active PR concentration, Et, was obtained by fitting the
experimental data from quasi-titration with amprenavir of WT
PR, mutant a (MVP-899/R1; Eberle et al., 1995) and four patient-
derived PR (PR 4 – 8) to equation (1). PR 6 was expressed two
times independently from the same patient material (PR 6a and
6b). The apparent kcat ([S]=10 µM) was calculated as kcat=vo/[Et].
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typically classified and scored by nucleotide sequencing
(Gehringer et al., 2003). The respective resistance of pa-
tient-derived PR to PI in our assay was expressed by en-
zymatic resistance factors (Renz) reflecting the ratio Ki (pa-
tient)/Ki (WT). These enzymatically determined resistance
factors were compared with genotypic resistance factors
(Rgen) derived from the number and nature of mutations
present in the predominant subpopulation (Tables 3 and
4). Table 3 shows that highly resistant PR (as expected
from their genotype) can be detected by their up to 2600-
fold reduced affinity (i.e. increased Ki) for the respective
PI. Obviously, the Ki even of heavily mutated proteases
(Rgen>10) could be determined in our assay. The affinity-
based resistance factors obtained with our assay show a
good overall correlation to the corresponding genotypic
resistance factors, but allow a much higher degree of dif-
ferentiation than the genotypic scores that are limited to
a range between 1 and 10.
The results shown in Table 4 suggest that PR classified
as ‘sensitive’ or ‘low resistant’ by the genotypic score
can be more precisely discriminated from WT PR in our
enzymatic assay, thus improving the sensitivity of detect-
ing resistant populations.
Defined Mixtures of Highly Resistant PR and WT PR
It has been previously shown by the HPLC-based activi-
ty assay that in mixtures of resistant PR and WT PR the
ratio between different ‘quasispecies’ remained un-
changed by simultaneous expression of their genes in E.
coli (Gehringer et al., 2003). We determined the resist-
ance factors with our fluorogenic assay after mixing WT
PR with different proportions of highly resistant patient-
derived PR. The enzymatic test was able to detect a frac-
tion as low as 5% saquinavir-resistant PR 205 within sen-
sitive WT PR (Table 5). 
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Table 2 Inhibition Constants (Ki) for WT PR of Five Therapeutic PI.
WT PR WT PR one-step WT PR one-step WT PR WT PRa
(purified >70%), purification, purification, (Klabe et al., (Markgren
cuvette cuvette microtiter plate 1998a) et al., 2000b)
PI KiC (nM) KiC (nM) KiM (nM) Ki (nM) Ki (nM)
APV 0.21±0.049 0.19±0.10 0.24±0.13 n.d. n.d.
IDV 0.16±0.028 0.29±0.075 0.15±0.056 0.14 0.31
NFV 0.38±0.032 0.37±0.046 0.36±0.146 0.28 0.54
RTV 0.16±0.035 0.16±0.023 0.16±0.035 0.17 0.59
SQV 0.066±0.011 0.11±0.089 0.085±0.045 0.15 0.23
Ki obtained in the cuvette (KiC) and in the microtiter plate (KiM) assay ± standard deviation. Abbreviations
for PI: APV, amprenavir; IDV, indinavir; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir; n.d., not deter-
mined.
aDetermined by HPLC analysis of the cleavage products of a peptide substrate.
bDetermined with the same fluorogenic peptide as in this study.
Table 3 Enzymatic and Genotypic Resistance Factors of Four Highly Resistant Patients.
Patient 38 Patient 66 Patient 202 Patient 205
(12 amino acid (15 amino acid (12 amino acid (12 amino acid
exchangesa) exchangesb) exchangesc) exchangesd)
PI RenzC Rgen RenzC Rgen RenzM Rgen RenzM Rgen
APV 1.6 2 3.1 2 11 4 433 6
IDV 12 >10 15 10 39 >10 343 >10
NFV 21 >10 37 10 40 >10 397 >10
RTV 17 8 48 10 45 >10 295 >10
SQV 298 >10 58 10 175 >10 2658 >10
The enzymatic resistance factors (Renz) were calculated from the Ki values determined in cuvette format
(RenzC) and microtiter plate format (RenzM). Resistance factors predicted from genotypic analysis (Rgen,
see Materials and Methods) are shown for comparison. For PI abbreviations see Table 2.
aL10I, S37N, I54L, D60E, L63P, I64V, A71V, G37S, V77I, I84V, L90M, I93L.
bK20R, E35D, M36I, S37N, M46L, R57K, I62V, L63P, A71V, I72R, G73S, V77I,
V82I, L90M, I93L.
cL10I, V11I, E35D, S37N, M46I, L63P, H69R, A71V, G73T, I84V, L90M, I93L.
dL10I, I15V, K20V, S37N, M46I, I62V, L63P, A71T, G73S, I84V, I85V, L90M.
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Discussion 
A phenotypic assay for testing resistance of HIV protease
to therapeutically used protease inhibitors has been de-
veloped, based on direct measurement of inhibition of
patient-derived enzymatically active PR using a low mo-
lecular weight synthetic substrate. In contrast to previous
approaches to determine the susceptibility of PR to in-
hibitors, this assay provides direct enzymatic data on the
affinity of the PI used in therapy for the HIV protease pop-
ulation of an individual patient, which are independent of
the total amount of active protease(s) present in the test.
An enzymatic assay of PR activity relying on analysis of
Gag-Pol cleavage products by ELISA after in vitro trans-
lation of the protease (Iga et al., 2002), has not yet been
applied to fresh patient-derived material.
The gene coding for patient-derived PR is obtained
from retroviral RNA extracted from blood plasma by tran-
scription to cDNA and amplification by a nested PCR us-
ing two different pairs of primers, and is finally expressed
in E. coli. A one-step acid purification procedure based
on the stability of PR at low pH (von der Helm et al., 1994)
leads to sufficient amounts of active protease for inhibi-
tion assays. As indicated by comparison with higher pu-
rified material (Table 2), residual E. coli proteins contained
in the one-step purified material do not interfere with the
determination of inhibition constants. Moreover, the inhi-
bition constants obtained with single-step purified WT
PR are very close to previously reported values for homo-
geneous WT PR (Klabe et al., 1998, Markgren et al.,
2001).
In a first approach, patient-derived PR has been ex-
pressed in E. coli using a similar procedure, starting from
patient DNA and measuring the recombinant HIV pro-
tease activity by HPLC analysis of the cleavage products
of a peptide substrate (Gehringer et al., 2003). It was
shown that the concentration of the respective PI result-
ing in a 50% enzyme inhibition (IC50) correlates well with
clinical parameters and blind genotypic analysis. More-
over, genotypic analysis revealed that the proportion of
different subpopulations is not significantly altered by the
amplification and cloning procedure, in contrast to cell-
culture based tests, where distinct subpopulations can
be selected depending on their replication capacities
(Kusumi et al., 1992). Extending the previous assay
(Gehringer et al., 2003), we have substituted HPLC
methodology by a continuous enzymatic assay with a flu-
orogenic peptide substrate, leading to essential improve-
ments of two aspects: (i) true inhibition constants (Ki) of
the tight-binding PI are determined, reflecting their ther-
modynamic affinity for the mutated PR over a wide range,
independent of the actual protease concentration and
experimental conditions; (ii) the microtiter plate format of
the assay allows high-throughput screening of a high
number of patient-derived samples within much shorter
time.
Although our novel assay has been evaluated on a lim-
ited number of patients up to now, it seems to be well
suited as a PR-based phenotypic resistance test in clini-
cal virology. The resistance factors calculated from the
measured Ki values correlate well with resistance factors
predicted from genotypic analysis (Tables 3 and 4). How-
ever, the range between ‘sensitive’ and ‘highly resistant’
proteases is expanded, allowing more precise differenti-
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Table 4 Resistance Profiles of Four Sensitive to Intermediate Resistant Patients.
Patient 64 Patient 68 Patient 71 Patient 4
(8 amino acid (7 amino acid (9 amino acid (4 amino acid
exchangesa) exchangesb) exchangesc) exchangesd)
PI RenzM Rgen RenzM Rgen RenzM Rgen RenzC Rgen
APV 1.4 1 0.46 1 0.46 1 4.2 2
IDV 2.1 1 0.87 1 3.3 1 3.4 2
NFV 3.3 1 3.0 1 5.8 3 5.0 3
RTV 2.1 1 1.4 1 3.9 1 4.0 2
SQV 3.6 1 1.3 1 6.6 3 8.2 3
For abbreviations see Tables 2 and 3.
aE35D, M36I, S37N, I62V, L63P, V77I, V82I, I93L.
bE35D, M36I, S37N, I62V, L63P, C67E, H69K.
cE35D, M36I, S37N, I62V, L63P, C67E, H69K, A71T, L90M.
dM36I/M, L63P, V77I, L90M.
Table 5 Enzymatic Resistance Factors Determined after Mix-
ing WT PR with Different Amounts of Highly Resistant PR.
Portion 10% 15% 5% 50% 
of patient PR #202 #202 #205 #205
APV 1.7 2.1 2.4 6.7
IDV 3.1 5.7 2.7 14.7
NFV 1.5 3.8 2.3 16.9
RTV 2.4 6.5 4.8 20.8
SQV 4.8 17.6 7.8 95.2
Highly resistant PR was obtained from patient #202 and patient
#205, respectively (see Table 3 for the corresponding resistance
profiles). For PI abbreviations see Table 2.
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ation. The clinical significance of different inhibition con-
stants within this range remains to be established in fu-
ture studies with an extended number of patients.
The Ki values for the inhibition of patient-derived re-
combinant HIV PR (e.g. 0.00016 µM for indinavir) are sev-
eral orders of magnitudes lower than the inhibitor con-
centrations that have been measured in blood plasma of
treated patients (e.g. 4.6 µM for indinavir; Langmann
et al., 2001) so that even highly resistant PR species
would be expected to be completely inhibited by the
plasma concentrations achieved in therapy. However, it is
known that, for reasons not completely understood,
much higher inhibitor concentrations than the thermody-
namic Ki values of isolated PR are required for significant
inhibition of intracellular virus replication. Extracellular
IC50 in the micromolar range have been reported for the
inhibition of virus replication in infected lymphocytes and
monocytes/macrophages (Perno et al., 1998). The PI
plasma levels achieved in therapy (Langmann et al.,
2001) are close to or frequently below the levels required
for 95% suppression of WT virus in vivo (e.g. 0.2 µM indi-
navir; Durant et al., 2000). In this situation, even a moder-
ate increase of Ki due to mutated PR could be responsi-
ble for therapeutic failure.
Concerning the evaluation of low or intermediate re-
sistant proteases, the fluorescence assay seems to be
significantly more sensitive than genotypic analysis
(Table 4). Even if proteases with a moderate increase of
inhibition constants would cause no clinically significant
resistance, these proteases are more likely to develop a
relevant mutation pattern (Gehringer et al., 2000). More-
over, low phenotypic resistance factors can also be
caused by highly resistant ‘quasispecies’ (Domingo et al.,
1985, 1995) present in a low percentage of the whole HIV
population. To simulate this condition in the enzymatic
test, we measured defined mixtures of highly resistant PR
and WT PR (Table 5). A portion of 5 – 10% highly resistant
PR was detected in these experiments. The resistance
factors for highly resistant patients can be more precise-
ly differentiated by our enzymatic assay than by genotyp-
ic analysis (Table 3). Exact quantitative discrimination be-
tween high resistance factors might be helpful in heavily
pre-treated patients to find inhibitors that are to some ex-
tent still effective in antiviral therapy (Miller, 2001).
As compared to cell culture-based phenotypic resist-
ance tests, the main advantages of our enzymatic assay
are the rapid and relatively inexpensive test procedure in
connection with its high sensitivity. Results of the enzy-
matic PR assay are available after one week (5 days for
amplification, cloning, expression and PR isolation;
5 h/patient for the microtiter plate inhibition test), while
cell culture-based tests usually require two to several
weeks. This may be important for example in acute HIV
infections or in infections during pregnancy, both indica-
tions for rapid resistance testing (EuroGuidelines Group
for HIV Resistance, 2001). The estimated price for resist-
ance determination with our assay is less than half the
cost of the commercially available phenotypic tests
(Flexner, 2000; Hanna and Caliendo, 2001). The sensitiv-
ity of our assay is an important advantage over cell cul-
ture-based tests, since the lower sensitivity of the cell
culture-based phenotypic assays is considered an inher-
ent drawback compared to genotypic tests (Rodriguez-
Rosado et al., 1999). For instance, these procedures can
reveal even highly resistant ‘quasispecies’ only when
they represent more than 10 – 40% of all relevant mole-
cules (Petropoulos et al., 2000). 
High sensitivity would be particularly desirable when
resistant ‘quasispecies’ are likely to be present in a low
proportion, as in primary infection before therapy is initi-
ated or when planning an intended therapy change for
other reasons than therapy failure, e.g. because of seri-
ous side effects. Resistant ‘quasispecies’ can quickly
constitute the majority of the HIV population after insuffi-
cient treatment has been initiated (Hanna and Caliendo,
2001). This may be avoided when resistant strains are de-
tected at an early stage and therapy is modified accord-
ing to the test results.
Of great practical importance is the fact that in our en-
tire assay procedure no potentially infectious HIV cell cul-
ture is utilized so that no special biosafety facility is re-
quired. An inherent limitation of our test is that it only
measures HIV PR resistance and has to be complement-
ed by a suitable enzymatic assay for resistance of RT to
its inhibitors (Garcia-Lerma et al., 1999; Vasquez-Rosales
et al., 1999).
In addition to resistance testing, the presented enzy-
matic assay may also be used in basic research as a tool
to characterize new PR mutants by their enzymatic pa-
rameters (Km, kcat) and by their inhibition profile with ther-
apeutic PI. Furthermore, it may provide information on
the ‘fitness’ of the respective HIV strain. This could be in-
teresting in view of ‘fitness’ assays that are expected to
be introduced as important diagnostic tools in the future
(Miller, 2001).
Since the prevalence of resistance and, as a conse-
quence, the spread of primary resistance is increasing
(Ristig et al., 2002) there is a growing interest to improve
the knowledge about the presence of resistant strains in
different populations (Miller, 2001). An enzymatic test like
the one presented here would be advantageous for test-
ing a large number of patient isolates with as little ex-
penses as possible. Cross-resistance is an important
problem particularly in therapy with PI, leading to resist-
ance toward antiretroviral drugs before their approval.
Thus several authors (Palmer et al., 1999; Harrigan and
Cote, 2000) recommend testing newly developed in-
hibitors against highly resistant clinical isolates. For this
purpose our test might be useful, because it is easily
standardized and suited for high-throughput screening.
In conclusion, the enzymatic assay for HIV PR resist-
ance described here seems to be a promising novel alter-
native to many established PR resistance assays and
should therefore be further evaluated in clinical studies
with a greater number of patients.
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Materials and Methods
Recombinant Expression of HIV PR 
The tested patient material was mainly obtained from J. Eberle,
Clinical Virology, Max von Pettenkofer Institute, Munich. RNA
was extracted from EDTA plasma using the ‘High Pure Viral Nu-
cleic Acid Kit’ (Roche, Mannheim, Germany) and reverse tran-
scribed into cDNA containing both the PR- and RT-gene. The
genes for these two enzymes were amplified in a first PCR round
using the primers geno1 and geno2 (designed by J. Eberle) and
the ‘Expand long template PCR system’ (Roche).
Geno1: 5´-GGC TGT TGG AAA TGT GGA ARR GA-3’
Geno2: 5´-GCY TGC CAA TAI TCY RTC CAC C-3’.
Cycle conditions: 2.5 units enzyme mix, 1.75 mM MgCl2, 0.35 mM
dNTP, annealing temperature 50°C, 35 cycles. The extraction of
RNA and the first PCR round were carried out together with the
genotypic resistance test in the section of clinical virology of the
Max von Pettenkofer Institute (see below). The second PCR
round was specific for the amplification of the PR-gene, using
the primers
P3: 5´-CGG GGS TCC TTC AGA GCA GAC CAG AG-3’ and
P4: 5´-GCC AAG CTT TCA AAA ATT TAA AGT GCA ACC AAT-3’.
Cycle conditions: 1.5 units AmpliTaq Gold, 3 mM MgCl2, 0.20 mM
dNTP, annealing temperature 48°C, 40 cycles. The PCR-reac-
tions were carried out in an UNO II thermocycler (Biometra, Göt-
tingen, Germany). The resulting amplicon was digested with
BamHI and HindIII (Roche) and ligated into the vector pBD2
(Bröker, 1986) digested with the same enzymes. The ligation
product was purified with QIAEX II Agarose Gel Extraction Kit
(Qiagen, Hilden, Germany) and transformed into TG1 electropo-
ration-competent E. coli cells (Stratagene, Heidelberg, Ger-
many). The overnight culture was expanded in 500 ml LB-medi-
um until an optical density of 0.4 to 0.6 was achieved. The cells
were disrupted by ultrasonification and the HIV PR was purified
by a one-step method (von der Helm et al., 1994) taking advan-
tage of its stability at low pH. Expression of the HIV PR in E. coli
cells and preparation of enzymatically active HIV proteases from
patient material are described in more detail elsewhere
(Gehringer et al., 2003). Subsequently, PR was precipitated with
ammonium sulfate and centrifuged. The pellet was dissolved in
200 – 500 µl assay buffer containing 10% DMSO and centrifuged
again. The PR solution could be used directly in the fluorescence
test or stored at – 20°C.
WT PR was highly purified exemplarily to check if contaminat-
ing E. coli proteins influence the enzymatic measurement. For
this purpose, we took advantage of its hydrophobicity: the pellet
from the ammonium sulfate precipitation was dissolved in a
smaller amount of assay buffer (100 – 200 µl) followed by cen-
trifugation. The supernatant contained most of the more hy-
drophilic E. coli proteins and was discarded. Dissolving the pel-
let again in 200 – 500 µl of assay buffer with 10% DMSO led to an
highly purified, but diluted PR solution that was concentrated
with a Centriprep-10 Concentrator (Amicon, Beverly, USA) fol-
lowing the instructor’s recommendations. The purity was
checked by Western Blot analysis. 
Measurement of PR Activity
WT or patient-derived active protease was tested with the
quenched fluorogenic peptide substrate DABCYL-γ-Abu-Ser-
Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS (10 µM) (Bachem, Heidel-
berg, Germany). Cleavage by the HIV PR leads to an increase in
fluorescence from the unquenched fluorophore EDANS. Differ-
ent concentrations of EDANS in assay buffer containing the sub-
strate were used for calibration (see Results and Figure 1).
Based on this calibration, the fluorescence data sampled at reg-
ular time intervals were converted into concentrations (nM) and
the reaction rates (nM×min– 1) were obtained from the slope of the
product concentration progress curves. 
The test was performed in assay buffer pH 4.7, containing
50 mM sodium acetate, 1 mM EDTA, 2.5 mM DTT, 1.0 M NaCl,
2.5% v/v glycerol, 10% v/v DMSO, 0.1% NP-40 (similar to the
buffer used by Kraft and Wang, 1994) and 10 µM of substrate. In
cuvette format, the fluorescence was measured in semi-micro
cuvettes (PMMA, 4×10 mm, Mueller Ratiolab, Dreieich-Buch-
schlag, Germany) containing a volume of 500 µl with a spectro-
fluorometer SFM 25 (BioTek-Kontron, Neufahrn, Germany),
equipped with an automated 4-sample changer (excitation:
355 nm; emission: 490 nm). In microtiter plate format, an assay
volume of 200 µl was used on 96-well plates (‘non-binding sur-
face’ microplates; Corning, Wiesbaden, Germany) measured
with a FL600 microplate reader (BioTek-Kontron) employing an
excitation filter of 340 nm (bandwidth 40 nm) and an emission fil-
ter of 485 nm (bandwidth 20 nm).
PR Inhibition by Therapeutical PI
PR inhibition experiments were performed with the following five
therapeutically used PI: amprenavir (APV), Glaxo Wellcome,
Greenford, UK; indinavir (IDV), Merck Research Laboratories,
Rahway, USA; nelfinavir (NFV), Agouron Pharmaceuticals Inc.,
La Jolla, USA; ritonavir (RTV), Abbott Laboratories, North Chica-
go, USA; saquinavir (SQV), Roche Products LTD., Welvyn Gar-
den City, UK.
In cuvettes, the initial rate of WT or patient derived PR was ad-
justed to 10 – 20 nM×min– 1 by addition of the proper amount of
enzyme solution and was observed for up to 15 min, before dif-
ferent concentrations of PI (0.25 – 2000 nM) were added. Typical-
ly, a new equilibrium was reached in ~1 min, the reaction was fol-
lowed for 20 – 30 min afterward.
On microtiter plates, the test was started with protease in
each well after premixing of different concentrations of PI,
buffer and substrate. The initial rates (10 – 20 nM×min– 1) were
obtained from control wells without PI. Scanning of the plate
(about 2 min per cycle) was continued over a total period of
40 – 50 min. On a first plate, the activity of the patient-derived
PR preparations (nM×min– 1×ml– 1) was determined for several
patients in parallel. A second plate was used for titration of pa-
tient-derived PR with amprenavir to obtain precise [Et] for eval-
uation (see below and Results). On this plate, amounts of pa-
tient-derived PR yielding an activity of 100 – 200 nM×min– 1 were
added to different concentrations of amprenavir (see Results for
details). One or two consecutive plates were required for a sin-
gle patient’s complete resistance profile to five currently in HIV-
therapy used PI. On the first plate, five ‘standard’ concentra-
tions of each of the five PI (typically 1, 2, 4, 8, and 32 nM) were
measured in duplicate. For precise Ki determination of sensitive
or highly resistant PR, a second plate with lower or higher PI
concentrations (in the range of 0.25 nM to 2 µM) was tested sub-
sequently, if necessary.
Evaluation of Inhibition Data
For each PI concentration the steady-state rate in the presence
of inhibitor, vi, was divided by the initial rate in the absence of in-
hibitor, vo. The resulting ratios vi/vo and the corresponding PI
concentrations were used to determine the inhibition constant
(Ki) of the investigated PI and PR by non-linear regression analy-
sis using the commercial software FigP from Biosoft (Cam-
bridge, UK).
Ki and the total concentration of active enzyme, [Et], were ob-
tained by fitting the data to the general equation for competitive
tight binding inhibitors (Morrison, 1969; Bieth, 1995):
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vi/vo = 1 – {[Et] + [It] + Kiapp – {([Et] + [It] + Kiapp)2– 4[Et][It]}1/2}/2[Et] (1)
where
vi=steady-state rate in the presence of the inhibitor, measured as
∆[product]min– 1;
vo=initial rate in the absence of the inhibitor;
[Et]=total concentration of the enzyme (free and bound);
[It]=total concentration of the inhibitor (free and bound);
Kiapp=apparent dissociation constant of the enzyme-inhibitor
complex at a given substrate concentration.
When both [Et] and Kiapp are treated as variable parameters, reli-
able estimates for [Et] but not for Kiapp are approached under
quasi-titration conditions, [Et]/Kiapp>10; otherwise, for [Et]<<Kiapp
(practically for [Et]/Kiapp<0.1), equation (1) simplifies to the equa-
tion for ‘classical’ inhibition in which [Et] is neglected
vi/vo = 1 / (1 + [It]/Kiapp) (2)
For competitive inhibition, the real Ki can be calculated from Kiapp
using the equation
Ki = Kiapp /(1+[S]/Km) (3)
where
[S]=substrate concentration and Km=Michaelis-Menten con-
stant.
Under our experimental conditions [S]<Km, Kiapp and Ki are simi-
lar, because competition of the inhibitor with the substrate is
negligible. Kiapp corresponds to the IC50, the inhibitor concentra-
tion resulting in 50% inhibition of the enzymatic activity under
defined experimental conditions.
To obtain resistance factors comparable to results of other
phenotypic tests, the Ki of patient HIV proteases were divided by
Ki of WT protease. 
Genotypic Resistance Analysis
The amplified PR gene (see top of Materials and Methods) was
sequenced with an ABI Prism 377 DNA sequencer (Applied
Biosystems, Weiterstadt, Germany) employing the Big Dye Mix
No. 4303150 (Perkin Elmer Life Sciences, Rogau-Juegesheim,
Germany). Genotypic resistance factors were obtained with an
in-house scoring algorithm using data from Beta-test available
at the Stanford HIV RT and Protease Sequence Database
(http://hivdb.stanford.edu/).
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